GA Gerhardt

First name:
GA
Last name:
Gerhardt
Stenslik, M. J., Potts, L. F., Sonne, J. W., Cass, W. A., Turchan-Cholewo, J., Pomerleau, F., et al. (2015). Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease. Journal Of Neuroscience Methods, 251, 120-9. https://doi.org/10.1016/j.jneumeth.2015.05.006 (Original work published 2015)
View
Fuqua, J. L., Littrell, O. M., Lundblad, M., Turchan-Cholewo, J., Abdelmoti, L. G., Galperin, E., et al. (2014). Dynamic changes in dopamine neuron function after DNSP-11 treatment: effects in vivo and increased ERK 1/2 phosphorylation in vitro. Peptides, 54, 1-8. https://doi.org/10.1016/j.peptides.2013.12.007
View
Littrell, O. M., Fuqua, J. L., Richardson, A. D., Turchan-Cholewo, J., Hascup, E. R., Huettl, P., et al. (2013). A synthetic five amino acid propeptide increases dopamine neuron differentiation and neurochemical function. Neuropeptides, 47(1), 43-9. https://doi.org/10.1016/j.npep.2012.08.004
View
Kelps, K. A., Turchan-Cholewo, J., Hascup, E. R., Taylor, T. L., Gash, D. M., Gerhardt, G. A., & Bradley, L. H. (2011). Evaluation of the physical and in vitro protective activity of three synthetic peptides derived from the pro- and mature GDNF sequence. Neuropeptides, 45(3), 213-8. https://doi.org/10.1016/j.npep.2011.03.003
View
Bradley, L. H., Fuqua, J., Richardson, A., Turchan-Cholewo, J., Ai, Y., Kelps, K. A., et al. (2010). Dopamine neuron stimulating actions of a GDNF propeptide. Plos One, 5(3), e9752. https://doi.org/10.1371/journal.pone.0009752 (Original work published 2010)
View
Stenslik, M. J., Evans, A., Pomerleau, F., Weeks, R., Huettl, P., Foreman, E., et al. (2018). Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques. Journal Of Neuroscience Methods, 303, 30-40. https://doi.org/10.1016/j.jneumeth.2018.03.006 (Original work published 2018)
View
Grondin, R., Littrell, O. M., Zhang, Z., Ai, Y., Huettl, P., Pomerleau, F., et al. (2019). GDNF revisited: A novel mammalian cell-derived variant form of GDNF increases dopamine turnover and improves brain biodistribution. Neuropharmacology, 147, 28-36. https://doi.org/10.1016/j.neuropharm.2018.05.014 (Original work published 2019)
View
Sompol, P., Furman, J. L., Pleiss, M. M., Kraner, S. D., Artiushin, I. A., Quintero, J. E., et al. (2017). Calcineurin/NFAT Signaling in Activated Astrocytes Drives Network Hyperexcitability in Aβ-Bearing Mice. The Journal Of Neuroscience : The Official Journal Of The Society For Neuroscience, 37(25), 6132-6148. https://doi.org/10.1523/JNEUROSCI.0877-17.2017 (Original work published 2017)
View
Thomas, T. C., Beitchman, J. A., Pomerleau, F., Noel, T., Jungsuwadee, P., Butterfield, D. A., et al. (2017). Acute treatment with doxorubicin affects glutamate neurotransmission in the mouse frontal cortex and hippocampus. Brain Research, 1672, 10-17. https://doi.org/10.1016/j.brainres.2017.07.003 (Original work published 2017)
View
Gash, D. M., Gerhardt, G. A., Bradley, L. H., Wagner, R., & Slevin, J. T. (2020). GDNF clinical trials for Parkinson's disease: a critical human dimension. Cell And Tissue Research, 382(1), 65-70. https://doi.org/10.1007/s00441-020-03269-8
View